These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1298 related items for PubMed ID: 23063373

  • 1. Immunologic effect and tolerability of intra-seasonal subcutaneous immunotherapy with an 8-day up-dosing schedule to 10,000 standardized quality-units: a double-blind, randomized, placebo-controlled trial.
    Pfaar O, Wolf H, Klimek L, Schnitker J, Wüstenberg E.
    Clin Ther; 2012 Oct; 34(10):2072-81. PubMed ID: 23063373
    [Abstract] [Full Text] [Related]

  • 2. Immunologic effects and tolerability profile of in-season initiation of a standardized-quality grass allergy immunotherapy tablet: a phase III, multicenter, randomized, double-blind, placebo-controlled trial in adults with grass pollen-induced rhinoconjunctivitis.
    Reich K, Gessner C, Kroker A, Schwab JA, Pohl W, Villesen H, Wüstenberg E, Emminger W.
    Clin Ther; 2011 Jul; 33(7):828-40. PubMed ID: 21741092
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and safety of specific immunotherapy with SQ allergen extract in treatment-resistant seasonal allergic rhinoconjunctivitis.
    Frew AJ, Powell RJ, Corrigan CJ, Durham SR, UK Immunotherapy Study Group.
    J Allergy Clin Immunol; 2006 Feb; 117(2):319-25. PubMed ID: 16461133
    [Abstract] [Full Text] [Related]

  • 4. Specific subcutaneous immunotherapy with recombinant grass pollen allergens: first randomized dose-ranging safety study.
    Klimek L, Schendzielorz P, Pinol R, Pfaar O.
    Clin Exp Allergy; 2012 Jun; 42(6):936-45. PubMed ID: 22909165
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Immunological effects and tolerability of a new fast updosed immunologically enhanced subcutaneous immunotherapy formulation with optimized allergen/adjuvant ratio.
    Pfaar O, Jung K, Wolf H, Decot E, Kleine-Tebbe J, Klimek L, Wüstenberg E.
    Allergy; 2012 May; 67(5):630-7. PubMed ID: 22385366
    [Abstract] [Full Text] [Related]

  • 7. Safety and immunological changes during sublingual immunotherapy with standardized quality grass allergen tablets.
    Malling HJ, Lund L, Ipsen H, Poulsen L.
    J Investig Allergol Clin Immunol; 2006 May; 16(3):162-8. PubMed ID: 16784009
    [Abstract] [Full Text] [Related]

  • 8. Treatment of seasonal allergic rhinoconjunctivitis with a once-daily SQ-standardized grass allergy immunotherapy tablet.
    Nelson H, Lehmann L, Blaiss MS.
    Curr Med Res Opin; 2012 Jun; 28(6):1043-51. PubMed ID: 22502864
    [Abstract] [Full Text] [Related]

  • 9. Short-term subcutaneous grass pollen immunotherapy under the umbrella of anti-IL-4: A randomized controlled trial.
    Chaker AM, Shamji MH, Dumitru FA, Calderon MA, Scadding GW, Makatsori M, Jones I, He QA, Subramanian KK, Arm JP, Durham SR, Schmidt-Weber CB.
    J Allergy Clin Immunol; 2016 Feb; 137(2):452-461.e9. PubMed ID: 26531865
    [Abstract] [Full Text] [Related]

  • 10. Effect of grass pollen immunotherapy with Alutard SQ on quality of life in seasonal allergic rhinoconjunctivitis.
    Powell RJ, Frew AJ, Corrigan CJ, Durham SR.
    Allergy; 2007 Nov; 62(11):1335-8. PubMed ID: 17714551
    [Abstract] [Full Text] [Related]

  • 11. Accelerated up-dosing of subcutaneous immunotherapy with a registered allergoid grass pollen preparation.
    Pfaar O, van Twuijver E, Hecker H, Boot JD, van Ree R, Klimek L.
    Int Arch Allergy Immunol; 2013 Nov; 160(4):420-4. PubMed ID: 23183541
    [Abstract] [Full Text] [Related]

  • 12. Efficacy of sublingual swallow immunotherapy in children with severe grass pollen allergic symptoms: a double-blind placebo-controlled study.
    Bufe A, Ziegler-Kirbach E, Stoeckmann E, Heidemann P, Gehlhar K, Holland-Letz T, Braun W.
    Allergy; 2004 May; 59(5):498-504. PubMed ID: 15080830
    [Abstract] [Full Text] [Related]

  • 13. Evaluation of recombinant and native timothy pollen (rPhl p 1, 2, 5, 6, 7, 11, 12 and nPhl p 4)- specific IgG4 antibodies induced by subcutaneous immunotherapy with timothy pollen extract in allergic patients.
    Rossi RE, Monasterolo G.
    Int Arch Allergy Immunol; 2004 Sep; 135(1):44-53. PubMed ID: 15286445
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Recombinant allergen-based monitoring of antibody responses during injection grass pollen immunotherapy and after 5 years of discontinuation.
    Gadermaier E, Staikuniene J, Scheiblhofer S, Thalhamer J, Kundi M, Westritschnig K, Swoboda I, Flicker S, Valenta R.
    Allergy; 2011 Sep; 66(9):1174-82. PubMed ID: 21480924
    [Abstract] [Full Text] [Related]

  • 17. Pretreatment IgE sensitization patterns determine the molecular profile of the IgG4 response during updosing of subcutaneous immunotherapy with timothy grass pollen extract.
    Schmid JM, Würtzen PA, Dahl R, Hoffmann HJ.
    J Allergy Clin Immunol; 2016 Feb; 137(2):562-70. PubMed ID: 26141262
    [Abstract] [Full Text] [Related]

  • 18. Clinical efficacy and safety of sublingual immunotherapy with tree pollen extract in children.
    Valovirta E, Jacobsen L, Ljørring C, Koivikko A, Savolainen J.
    Allergy; 2006 Oct; 61(10):1177-83. PubMed ID: 16942565
    [Abstract] [Full Text] [Related]

  • 19. Clinical efficacy of microencapsulated timothy grass pollen extract in grass-allergic individuals.
    TePas EC, Hoyte EG, McIntire JJ, Umetsu DT.
    Ann Allergy Asthma Immunol; 2004 Jan; 92(1):25-31. PubMed ID: 14756461
    [Abstract] [Full Text] [Related]

  • 20. Evaluation of serum IgG4 antibodies specific to grass pollen allergen components in the follow up of allergic patients undergoing subcutaneous and sublingual immunotherapy.
    Rossi RE, Monasterolo G, Coco G, Silvestro L, Operti D.
    Vaccine; 2007 Jan 15; 25(5):957-64. PubMed ID: 17045368
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 65.